Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185640 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 303
- Enrollment target
NCT00185640: Completed Phase 2 study, sponsored by Stanford University.
NCT00185640 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 303 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00185640, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 303 participants
- Enrollment target
Study Summary
To measure how frequently and to what degree a complication of transplant cell acute graft versus host disease (GvHD) occurs.
Interventions
- DRUG Filgrastim
- DRUG Cyclosporine
- DRUG Anti-thymocyte globulin (ATG)
- DRUG Mycophenolate mofetil (MMF)
- RADIATION Total Lymphoid Irradiation (TLI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2003-03 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00185640
The ClinicalTrials.gov registry entry for NCT00185640 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Filgrastim is the first listed.
NCT00185640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00185640 about?
NCT00185640 is a clinical study titled "Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies". To measure how frequently and to what degree a complication of transplant cell acute graft versus host disease (GvHD) occurs.
What is the current status of trial NCT00185640?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 303 participants. The study started on 2003-03. Estimated completion is 2016-01.
What interventions are being tested in trial NCT00185640?
The interventions under investigation include: Filgrastim (DRUG), Cyclosporine (DRUG), Anti-thymocyte globulin (ATG) (DRUG), Mycophenolate mofetil (MMF) (DRUG), Total Lymphoid Irradiation (TLI) (RADIATION).
Who is sponsoring clinical trial NCT00185640?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.